Heart failure with a normal ejection fraction (HFNEF) now comprises more than 50 % of all patients with heart failure. As the population ages, HFNEF will continue to be a growing public health problem. Recent studies highlight the heterogeneity of this syndrome with regards to underlying pathophysiologic mechanisms. It has been recognized that multiple physiologic domains of cardiovascular function are abnormal in afflicted patients resulting in a reduced reserve capacity, which contributes in an integrated fashion to produce the observed phenotype. Additionally, the realization that differing aspects of this syndrome (eg, exercise limitations, pulmonary edema, and labile blood pressure) likely each have distinct physiologic causes further adds to the complexity. As a result of the heterogeneous nature of the pathophysiologic processes and comorbid illnesses in this population, there is a wide range of clinical outcomes. Accordingly, appreciation of the global nature of HFNEF ideally will better inform optimal design for future diagnostic and therapeutic strategies. Completed clinical trials have not resulted in any evidence-based treatments available for improving survival. Given the disappointing results of these investigations, there has been renewed interest in developing interventions that target underlying comorbidities and peripheral mechanisms. Additionally, nonpharmacologic interventions such as diet and exercise have shown promise in early, small clinical investigations. Finally, methods to more rationally subgroup patients to identify cohorts that could respond to targeted intervention are essential. Recognizing the success achieved in the treatment of systolic heart failure, or heart failure with a reduced ejection fraction (HFREF) by addressing neurohormonal and renal mechanisms, new therapies for HFNEF may be achieved by a similar shift in attention away from the heart.
Introduction
Heart failure with a normal ejection fraction (HFNEF) has now supplanted heart failure with a reduced ejection fraction (HFREF) as the most common cause of heart failure, accounting for over 50 % of all cases [1] [2] [3] . These patients are typically elderly and female, and have a high incidence of medical comorbidities, including hypertension, diabetes, renal dysfunction, obesity, anemia, frailty, and coronary artery disease [4] [5] [6] . Despite its well-elucidated epidemiology, however, there is still considerable controversy over the pathophysiology of HFNEF.
HFNEF was formerly referred to as diastolic heart failure because many investigators thought the primary disorder was that of diastolic rather than systolic function [7] [8] [9] [10] . Indeed, these patients were noted to have myocardial hypertrophy and interstitial fibrosis associated with increased ventricular stiffness and prolonged ventricular relaxation [10] . As such, diagnostic algorithms were generated to evaluate these variables both by cardiac catheterization and noninvasively through echocardiography utilizing patterns of blood flow and tissue velocities [11, 12] . However, these properties also have been noted in patients with HFREF as well as those without heart failure [13] . To confirm the presence of diastolic dysfunction, the end-diastolic pressure-volume relation (EDPVR) can be utilized, which should shift upward demonstrating both elevation of left ventricular end-diastolic pressures as well as decreased ventricular capacitance [5] . While precisely this abnormality was presumed to occur in patients with HFNEF, more recent studies have indicated that most HFNEF patients have either no or rightward shifting of the EDPVR curve (as do those with HFREF), whereas left and upward shifts occur in those patients with true diastolic dysfunction (eg, amyloidosis or restrictive cardiomyopathy) [14, 15] . Moreover, recent investigations examining exercise intolerance in HFNEF patients have concluded that these limitations are likely not due to diastolic dysfunction, but rather are secondary to peripheral, noncardiac factors [16••] .
As such, the scope of HFNEF research has broadened in recent years in an attempt to define the pathophysiologic mechanisms that underlie this disease. One of the larger contributing factors to this entity is volume overload and a documented sensitivity to sodium-induced expansion of the intravascular and extravascular space that occur in HFNEF as well as HFREF patients [17, 18] . Such intravascular volume expansion can result in statistically significant differences in left ventricular end-diastolic volumes [15, 19, 20] . In one large trial, in comparison to normal patients, HFNEF patients had markedly greater left ventricular end-diastolic volumes (145±40 mL versus 67±12 mL) [21] . Further, the multiple comorbidities typically found in HFNEF (obesity, renal dysfunction, anemia) are associated with volume overload, and indeed multiple studies investigating human and animal models have indicated that HFNEF patients are chronically volume overloaded despite normal ejection fraction (EF) [22] [23] [24] . Other potential nondiastolic mechanisms include chronotropic incompetence [25] , altered ventriculovascular coupling [14, 26, 27] , left atrial (LA) dilation and concomitant atrial systolic failure [28] , endothelial dysfunction [17, 29] and altered skeletal muscle oxidative capacity.
Unlike HFREF, where evolving medical treatments and treatment regimens have decreased mortality and hospitalizations, hospitalizations for HFNEF have increased over the past 15 years from 38 % to 54 % and mortality rates remain high at greater than 50 % over 5 years from the time of diagnosis [2] . While pharmacologic treatment is the mainstay of HFREF management, medical therapy has thus far shown no mortality benefit in patients with HFNEF in large randomized controlled trials such as Candesartan in Heart Failure-Assessment Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers . & A small study by Warner et al. [48] suggested ARBs may improve exercise tolerance in HFNEF patients. In 20 patients with EF greater than 50 % and echocardiographic evidence of diastolic dysfunction, the addition of losartan to their regimen showed a significant improvement in exercise tolerance versus placebo [48] . It was suggested that perhaps this was secondary to blunted peaks and rate of change of systolic blood pressure during exercise. & ACEIs and ARBs are encouraged as treatment for the comorbidities associated with HFNEF (eg, diabetes, renal dysfunction) that are thought to contribute to volume overload and exacerbations, however, have little supporting evidence as HFNEF-specific therapy [36].
β-Blockers
& β-Blockers have been suggested as useful treatments in HFNEF because their rate control effects lengthen diastole and filling time, and thereby mediate against diastolic dysfunction [49] . However, as previously discussed, ventricular overfilling and not inability to fill (eg, diastolic dysfunction) is a predominant mechanism, and as such, β-blocker use in these patients is of unclear benefit. & In the SENIORS trial, a large randomized controlled trial examining the effect of nebivolol on mortality and hospitalization in patients aged 70 years or older with a hospitalization for heart failure within the past year or an EF of 35 % or less, a subanalysis of patients with EF above 35 % showed no improvement in the primary outcome of combined mortality and hospitalizations when nebivolol was used versus control patients over an average 21-month period [34] . & The ACC/AHA has recommended rate control for HFNEF patients with concomitant atrial fibrillation given its high prevalence in this population (30 %-40 %), as well as its association with worse function class, quality of life, 6-min walking distance, and left atrial enlargement [30, 50] . This is thought to be secondary to increasing heart rates, loss of atrial systole, irregular cycle lengths, and its periodicity in nature [50] . & Conversely, however, chronotropic incompetence is thought to play a central role in the pathophysiologic mechanism of HFNEF, and is a known contributor to decreased exercise tolerance in these patients, calling β-blocker use into question [17, 27] . & As a HFNEF therapy, β-blockers have yet to demonstrate a mortality or hospitalization benefit in this population [36] .
Calcium channel blockers
& Calcium channel blockers were suggested for treatment of HFNEF patients for their rate control effects, but also as a way to increase lusitropy based on reported benefits in those with hypertrophic cardiomyopathy [51, 52] . However, no large randomized controlled trials have examined their efficacy in HFNEF. & A small study examined the effects of verapamil on 20 male patients, aged 68±5 years with EF above 45 %. It showed a benefit in exercise capacity by 33 % and peak filling rates by 30 % [53] . However, in addition to the small sample size of this study, the patients examined in earlier studies often unintentionally included younger patients with restrictive or hypertrophic cardiomyopathies [3] . & The benefit of rate control afforded by calcium channel blockers was previously discussed in the [57] . Notably, there was a 64 % reduction in the incidence of heart failure (95 % CI, 42-78, PG0.001) in this cohort, although HFNEF versus HFREF was not delineated. Recall, however, that elderly patients are more typically characteristic of the HFNEF population. & Concern regarding "overdiuresis" exists within the HFNEF population due to the notable preload sensitivity of patients with true upward and leftward shifts of the EDPVR. This has not borne out in the broader HFNEF population, however, as even with aggressive diuresis as is typical of treatment for acute pulmonary edema, most patients do not need blood pressure support [8, 24, 58] . Worsening renal function in HFNEF patients when prescribed diuretics may be more attributable to alterations in ventricular vascular coupling with age, which has been shown to result in greater alterations in blood pressure in older as compared to younger individuals [59, 60] . & Repeat exposure and chronic diuretic use has been associated with decreased efficacy, residual pulmonary congestion, and electrolyte abnormalities, which can result in increased hospitalizations and mortality [24, 61] .
Digoxin
& Digoxin is a well-studied and widely used pharmacologic agent in HFREF. It was historically thought of as contraindicated in patients with HFNEF, however, based solely on anecdotal reports or prior nonrandomized trials [62] . & However, like β-blockers and calcium channel blockers, digoxin has been postulated to provide potential benefits in those patients with HFNEF and concomitant atrial fibrillation. & In conjunction with the widely known DIG study, the DIG ancillary study evaluated digoxin in 988 patients with EF above 45 %. There were no significant reductions in the amount of hospitalizations or mortality secondary to heart failure, although trends toward decreased hospitalization and improved exercise tolerance were noted [33] . & As such, according to the ACC/AHA digoxin has not been shown to minimize symptoms of heart failure, and therefore remains a Class IIb, level of evidence C recommendation in HFNEF [36].
Aldosterone receptor antagonists
& Despite the absence of data supporting ACEIs and ARBs in HFNEF, the RAAS system has still been of considerable interest in HFNEF treatment, in particular the role of the aldosterone receptor. & Aldosterone has specifically been associated with renal, vascular, and myocardial fibrosis and is noted as a critical component in resistant hypertension [63, 64] . Further, aldosterone antagonism has shown significant benefit in patients with HFREF [65] [66] [67] 
Interventional procedures Percutaneous coronary intervention and coronary artery bypass surgery
& The link between coronary artery disease and HFNEF has been well established, but its role remains controversial [70, 71] . Some studies support the role of myocardial ischemia resulting in increased stiffness and upward shifting of the EDPVR curve [72, 73] . Others suggest that HFNEF represents early compensation for myocardial dysfunction, which ultimately progresses into HFREF, the initiators of which are coronary artery disease and myocardial infarction [74] [75] [76] . & Kramer et al. [77] examined 46 patients hospitalized with flash pulmonary edema in the setting of poorly controlled hypertension. It was noted that recurrence of pulmonary edema (or death) was not only similar between patients with EF less than and greater than 40 %, but also between those patients who were and were not revascularized despite the presence of coronary artery disease. & As such, the ACC/AHA recommends pursuit of revascularization if symptomatic myocardial ischemia is judged to be contributing to the worsening of cardiac function in HFNEF patients [36] ; however, no long-term randomized investigations have been performed for this specific population.
Aortic valve replacement
& It is well established that the development of heart failure in aortic stenosis portends a poor prognosis, with a median survival of 2 years [78] . & About 60 % of these patients develop heart failure with a preserved ejection fraction (≥ 50 %), thought to be due to myocardial hypertrophy and the deterioration of ventricular compliance [79, 80] . & According to the ACC/AHA, in the setting of severe aortic stenosis (aortic valve areaG1.0 cm 2 , mean aortic valve gradient940 mmHg, or aortic jet velocity94.0 m/s), symptomatic HFNEF should be managed with aortic valve replacement [81, Class I] . Symptom and survival improvement are similar to those patients with reduced EF. & For those patients with severe aortic stenosis, HFNEF and paradoxically low-flow states, prognosis has actually been shown to be worse when compared to HFNEF patients with normal flow states. One study looked at 331 patients with EF of 50 % or above and an aortic valve area smaller than 0.6 cm 2 , and it was noted that low-flow states were associated with lower 3-year survivals (76 % vs 86 %, P=0.006) [82] . & Transcatheter aortic valve replacement (TAVR) is an evolving therapy for aortic stenosis. Although no studies have examined outcomes in HFNEF patients specifically, subgroup analysis of patients with high-risk aortic stenosis and EF greater than 55 % show no difference in survival whether undergoing TAVR or surgical replacement [83] . & HFNEF is not only relegated to aortic stenosis, but also may be seen in aortic insufficiency. While mortality rates above 20 % annually have been reported for patients with aortic insufficiency, these studies did not measure LV function specifically, and therefore, the effect of EF on prognosis is unclear [84, 85] . However, subsequent data has shown poor outcomes for medically treated patients regardless of EF [86, 87] . & Like severe aortic stenosis, in symptomatic aortic regurgitation, aortic valve replacement is indicated regardless of ejection fraction [81, Class I].
Physical/speech therapy and exercise & Exercise intolerance (manifested by exertional dyspnea, fatigue, or anergia) in HFNEF patients is not only the most common symptom of HFNEF, but is also a cause of decreased quality of life and a predictor of mortality [2, 19, 88, 89] . & It has been demonstrated that peak exercise oxygen uptake (VO 2 ) is a valid and reproducible target for assessing exercise intolerance in patients with heart failure, and notably is consistently decreased in HFNEF patients compared with age-matched healthy volunteers, and to a similar degree as in HFREF [16••, 90] . This is further compounded by the observation that VO 2 declines by up to 10 % per decade in healthy older adults [91, 92] . & The decline in VO 2 could be secondary to either a decreased cardiac output (CO) or a decline in arterial-venous extraction, as predicted by the Fick equation. The declines in CO with exercise have been postulated to result as result of a blunted chronotropic response, whereas decreases in the arterial-venous extraction has been attributed to multiple potential sources, including impaired peripheral vascular function and/or musculoskeletal function [16••] . & A recent study noted benefits of 16 weeks of exercise training performed 3 days a week in 53 HFNEF patients aged 70±6 years. Specifically, when compared to control patients, these patients had significantly better VO 2 , peak power output, exercise time, 6-min walk distance, and ventilator anaerobic threshold [88] . Of note, there was also a significant improvement in the physical aspect of the quality of life score, but not in the total. Similar studies by Gary et al. [93] and Smart et al. [94] also have demonstrated improvements in exercise tolerance, as well as quality of life in conjunction with exercise therapy. The increase in VO 2 in this cohort was predominately mediated by peripheral effects and not changes in CO with exercise. & Exercise training therefore can be utilized with symptomatic benefit as well as improvement in quality of life in the HFNEF population.
Emerging therapies
& The benefit of cardiac resynchronization therapy (CRT) in HFREF is well established in those with mechanical and electrical ventricular dyssynchrony [95, 96] . However, the role of the aforementioned in HFNEF is only now being examined as a potential therapeutic target, with small studies suggesting that it is less prevalent than in HFREF, but is still significant [97, 98] . Currently, the Karolinska-Rennes (KaRen) study is being conducted to evaluate potential CRT benefits in the HFNEF population [99] . & Given the greater activity of the sympathetic nervous system in the elderly, and its contributions to hypertension, renal dysfunction, vascular stiffness, and myocardial ischemia, its role in HFNEF is currently under evaluation [100] . The Rheos system (CVRx, Minneapolis, MN), an implantable electrical device linked to the carotid baroreceptor, is currently being studied to determine if this system can impact outcomes in HFNEF patients. Prior studies have already shown benefit in reducing arterial pressures, heart rate, and left ventricular mass [101] . & Similarly, there has been an increasing focus on renal sympathetic innervation, as it is linked to the renal vasculature, tubules, and juxtaglomerular apparatus and, consequently, to sodium reabsorption and the RAAS [102] . Some experiments have utilized renal denervation in resistant hypertension and have shown favorable changes in blood pressure, renal function, and cardiac hypertrophy. The SIMPLICITY-3 trial is currently ongoing to evaluate percutaneous radiofrequency ablation of renal sympathetic nerves in resistant hypertension. A small related study, SIMPLICITY-HF, is currently enrolling patients to further assess this strategy. & Given the prominent role of hypertension in HFNEF, the RESPeRATE device (InterCure, Inc., New York, NY) also may prove to have some benefit. This device utilizes biofeedback in combination with slower respiration rates to manipulate cardiac and pulmonary sympathetic outflow to decrease blood pressure. Preliminary studies have shown reliable decreases in both systolic and diastolic blood pressures and may ultimately show benefit in HFNEF patients [103] .
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